Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors

#143

Introduction: In the absence of preoperative somatostatin receptor (sst) scans, knowledge of immunohistochemical sst2 tumor expression may help in predicting the success of somatostatin analogue-based follow-up studies and treatment of neuroendocrine tumors (NETs).

Aim(s): We studied the association between sst immunostaining and tracer uptake in [111In]-DTPA octreotide (DTPAOC) scintigraphy and [68Ga]-DOTA-D-Phe(1)-Tyr(3)-Octreotide (DOTATOC) positron emission tomography (PET)/computed tomography (CT).

Materials and methods: Retrospective analysis of 36 NET patients. In 40 tumors, immunohistochemical sst2, sst3, and sst5 expression was analysed using a pathological scoring, applying monoclonal (sst2) or polyclonal antibodies (sst3, sst5). In 14 lesions, [111In]-DTPAOC uptake was assessed by a semiquantitative score. In 26 tumors, [68Ga]-DOTATOC PET/CT was quantified using an uptake score and maximal standard uptake value (SUVmax).

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Müssig K, Öksüz M, Dudziak K, Ueberberg B, Wehrmann M,

Keywords: neuroendocrine tumors, NET, sst, [68Ga]-DOTA-Tyr-octreotide, [111In]-DTPAOC,